Standard CXL better at stabilizing progressive keratoconus

Article

Benzalkonium chloride-assisted (BAC) transepithelial collagen crosslinking (CXL) with 0.5% proparacaine drops is less effective than standard CXL in patients with progressive keratoconus

Benzalkonium chloride-assisted (BAC) transepithelial collagen crosslinking (CXL) with 0.5% proparacaine drops is less effective than standard CXL in patients with progressive keratoconus, claims a study in the Journal of Cataract and Refractive Surgery.

The study, headed by Dr Carina Koppen, Department of Ophthalmology, Antwerp University Hospital, Belgium, enrolled 53 eyes of 38 keratoconus patients. The Placido disk device was used to measure sphere, cylinder, as well as maximum keratometry (K max) simulated K values and refractive power values.

Standard CXL was preceded by administration of proparacaine drops 0.5% preserved with BAC 0.005% every five minutes during a thirty minute time period. Results were compared before CXL and post-CXL at 6, 12 and 18 months.

Only corrected distance visual acuity demonstrated a statistically significant improvement at six and twelve months postoperatively. Standard CXL was significantly more effective in stabilizing progressive keratoconus.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.